Intercept Pharmaceuticals Stock Operating Margin
Intercept Pharmaceuticals fundamentals help investors to digest information that contributes to Intercept Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Intercept Stock. The fundamental analysis module provides a way to measure Intercept Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intercept Pharmaceuticals stock.
Intercept |
Intercept Pharmaceuticals Company Operating Margin Analysis
Intercept Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Intercept Pharmaceuticals Operating Margin | 0.02 % |
Most of Intercept Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intercept Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Intercept Pharmaceuticals has an Operating Margin of 0.0185%. This is 100.05% lower than that of the Biotechnology sector and 100.02% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.34% lower than that of the firm.
Intercept Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intercept Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intercept Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Intercept Pharmaceuticals by comparing valuation metrics of similar companies.Intercept Pharmaceuticals is currently under evaluation in operating margin category among its peers.
Intercept Fundamentals
Return On Equity | -0.64 | |||
Return On Asset | -0.0723 | |||
Profit Margin | (0.19) % | |||
Operating Margin | 0.02 % | |||
Current Valuation | 695.84 M | |||
Shares Outstanding | 41.81 M | |||
Shares Owned By Insiders | 3.12 % | |||
Shares Owned By Institutions | 81.30 % | |||
Number Of Shares Shorted | 10.19 M | |||
Price To Earning | (3.88) X | |||
Price To Book | 44.19 X | |||
Price To Sales | 1.60 X | |||
Revenue | 285.71 M | |||
Gross Profit | 284.73 M | |||
EBITDA | (61.7 M) | |||
Net Income | (174.86 M) | |||
Cash And Equivalents | 404.78 M | |||
Cash Per Share | 13.58 X | |||
Total Debt | 332.67 M | |||
Debt To Equity | 411.20 % | |||
Current Ratio | 3.22 X | |||
Book Value Per Share | 1.72 X | |||
Cash Flow From Operations | (26.78 M) | |||
Short Ratio | 2.64 X | |||
Earnings Per Share | (4.26) X | |||
Price To Earnings To Growth | (0.69) X | |||
Target Price | 19.0 | |||
Number Of Employees | 341 | |||
Beta | 0.88 | |||
Market Capitalization | 794.36 M | |||
Total Asset | 553.71 M | |||
Retained Earnings | (2.14 B) | |||
Working Capital | 310.05 M | |||
Current Asset | 641.69 M | |||
Current Liabilities | 47.37 M | |||
Z Score | -3.15 | |||
Net Asset | 553.71 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Stocks Directory Find actively traded stocks across global markets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |